In short
Clinical trials investigating ATOVAQUONE are studying its use in malaria prevention. This article summarizes a Phase 2 study in healthy, non-immune volunteers to measure how well a weekly oral atovaquone-proguanil regimen protects against malaria and to assess safety.
Key points
- Clinical trials investigating ATOVAQUONE in the provided data are focused on malaria prevention. The main study is a Phase 2 interventional trial in 32 non-immune healthy volunteers. Researchers are testing a weekly oral atovaquone-proguanil regimen and measuring how many volunteers stay protected after malaria challenge exposure. The study also tracks safety as a primary outcome. The key question is whether this preventive approach can stop parasite growth in the blood after exposure.
Trial overview
This clinical research is studying ATOVAQUONE in a malaria prevention setting. The provided trial is a Phase 2 interventional study with the title “Antimalarial prophylactic efficacy of a weekly dose atovaquone-proguanil.”
The study status is Authorised, and the planned enrollment is 32 participants. The trial is focused on whether weekly oral atovaquone-proguanil can protect people from malaria after controlled exposure to the parasite.
Who can participate
The study is designed for non-immune healthy volunteers. This means the volunteers are healthy and do not already have protection against malaria.
Because the study is testing prevention, the target group is not people with active malaria disease. Instead, the trial looks at whether the study medicine can help prevent infection after exposure in a controlled research setting.
What is being tested
The main preventive treatment being studied is oral atovaquone-proguanil, given as 250/100 mg weekly. The trial title and summary both show that the study is evaluating the prophylactic, or preventive, effect of this regimen.
The trial also includes PfSPZ Challenge (NF54), which is given by intravenous injection as part of the malaria challenge model. A placebo-like capsule containing microcrystalline cellulose PH102 is also listed among the interventions.
In simple terms, the study compares how people do after planned malaria exposure when they receive the preventive medicine.
Trial phase and design
This is a Phase 2 study. Phase 2 trials usually look more closely at whether a treatment works and continue to check safety in a smaller group of people.
The study is interventional, which means the researchers assign study treatments and then measure the results. The design uses a malaria challenge approach, where volunteers are exposed to PfSPZ Challenge NF54 so researchers can see whether the preventive regimen works.
Outcomes being measured
The main efficacy outcome is the proportion of protected volunteers. Protection is defined as no amplifying parasitaemia in the blood for 21 days after challenge exposure.
Amplifying parasitaemia means the parasite level in the blood rises over time, based on qPCR testing. The trial defines this as at least one qPCR result above 20 blood-stage parasites per mL, followed by another qPCR result showing at least a 4-fold increase 24 to 48 hours later.
The primary safety endpoint is also listed, showing that the study is not only asking whether ATOVAQUONE-based prevention works, but also whether it can be studied safely in this volunteer group.
Why this study matters
Malaria prevention studies help researchers test whether a medicine can stop infection before it starts. This trial is important because it uses a controlled challenge model, which can give early evidence about protective effect in a small group of volunteers.
The current data show one authorised Phase 2 study of ATOVAQUONE-related prevention in healthy, non-immune adults, with protection against malaria and safety as the main goals.